TSTickerStarGet alerts

Valion Bio closes $700,000 Series B preferred-stock and warrant sale to 3i

On November 6, 2026, Valion Bio issued 700 Series B non-voting convertible preferred shares and warrants for 21,539 common shares to 3i, LP for $700,000. The warrants have an initial exercise price of $0.5182 per common share, and the securities were sold in reliance on Section 4(a)(2) and/or Rule 506(b) exemptions. The side letter provides registration rights and extends the Series B purchase agreement termination date to December 9, 2027.

Share this story

Key takeaways

  • Closing consideration: 3i, LP paid Valion Bio $700,000 for the Series B securities on November 6, 2026.

  • Securities issued: Valion Bio issued 700 Series B non-voting convertible preferred shares and warrants to purchase 21,539 common shares.

  • Warrant pricing: The Series B warrants have an initial exercise price of $0.5182 per common share.

  • Unregistered sale: The securities were issued in reliance upon an exemption under Section 4(a)(2) and/or Rule 506(b) of the Securities Act.

  • Registration rights: Valion Bio agreed to use commercially reasonable efforts to file a resale registration statement within 30 days after closing, seek effectiveness within 60 days after closing, and maintain availability for resale until the securities are sold or no longer require registration.

  • Agreement deadline: The termination date for closings under the Series B Preferred Purchase Agreement was extended to December 9, 2027.

  • Remaining Series B option: As of November 6, 2026, 3i retained an option, but not an obligation, to purchase up to 1,550 additional Series B preferred shares and corresponding warrants for up to $1,550,000.

Key metrics

Series B closing purchase priceNovember 6, 2026
$700,000
Series B preferred shares issuedNovember 6, 2026
700 shares
Series B warrant underlying sharesNovember 6, 2026
21,539 common shares
Series B warrant initial exercise priceNovember 6, 2026
$0.5182 per share
Series B purchase agreement maximumAs of November 6, 2026
Up to $8,400,000 for up to 8,400 preferred shares and corresponding warrants
Remaining Series B purchase optionAs of November 6, 2026
Up to 1,550 preferred shares and corresponding warrants for up to $1,550,000
Series C preferred shares purchased to dateAs of November 6, 2026
13,637 shares for $13,637,000
Additional Series C purchase optionAs of November 6, 2026
Up to 23,863 preferred shares and corresponding warrants for up to $23,863,000

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow VBIO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert